Charles Russell Speechlys has advises Kreos Capital on the sale of Creabilis plc
Charles Russell Speechlys has advised Kreos Capital on the sale of its stake in Creabilis plc, a privately held specialty pharmaceutical company focused on developing first-in-class topical treatments for common inflammatory skin conditions, including psoriasis, atopic dermatitis and pruritus (itch) to Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company. Under the terms of the agreement, Sienna will make an undisclosed upfront payment in cash and stock, as well as additional payments contingent upon achieving specific regulatory and commercial milestones, which could exceed $150 million in aggregate.
“The acquisition of Creabilis is transformative, expanding Sienna’s innovative and diversified pipeline,” said Sienna President and Chief Executive Officer Frederick C. Beddingfield III, M.D., Ph.D., who formerly developed leading dermatology and aesthetics brands such as BOTOX® Cosmetic, JUVÉDERM®, LATISSE®, KYBELLA®, ACZONE® and TAZORAC®. “Both the TrkA and TrkA/JAK3 programs offer the potential of highly differentiated topical treatments for inflammatory skin diseases and pruritus. Furthermore, the addition of the groundbreaking “Topical by Design” technology will allow Sienna to discover and develop innovative new drug candidates for areas of high unmet need in dermatology.
Chris Putt commented, “The complexity of project managing the multiple jurisdictions this deal spanned across, is further evidence of our international reach and shows our Luxembourg office’s strength in the financial services sector.”
News & Insights
Charles Russell Speechlys advises Country Court Care on refinancing
Country Court’s portfolio currently comprises 30 freehold care homes, with seven opened over the past two years.
Charles Russell Speechlys joins ELITE partner programme to help ambitious UK businesses succeed
ELITE is London Stock Exchange Group’s international business support and capital raising programme for private growth companies.
Malcolm MacDougall ranked top place in UK’s ranking for most active deal lawyer by volume
The league tables are compiled by deals announced in the first half of 2018 and which are available on Mergermarket’s deals database.
Charles Russell Speechlys ranked top place by deal value in the East of England
The results were in the recent Experian MarketIQ report, showing the firm’s total value for deals in the East of England as £1,202,000,000.